Loading
A phase 1/2 trial of capecitabine and pembrolizumab in triple-negative breast cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.
A Study of Tetrathiomolybdate (TM) Plus Capecitabine is a phase 1/2, randomised interventional study registered as NCT06134375 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 204 participants, started 2024-11-26 and due to reach its primary completion in 2031-06-26. Interventions recorded: Tetrathiomolybdate; Capecitabine; Pembrolizumab. Conditions listed: Triple Negative Breast Cancer; Residual Disease. Triple-negative eligibility wording from the registry: "Patients must have histologically confirmed breast malignancy that is Triple negative tumors as defined as ER and PR \<1% and HER2 negative as per ASCO/CAP guidelines". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Pembrolizumab and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/